Torino, Italy — October 7, 2025 — Leads & Copy — Resalis Therapeutics presented new preclinical results on its lead candidate RES-010 at the European Association for the Study of Diabetes (EASD) in Vienna, Austria, the Obesity Science & Innovation Meeting in Boston, MA, and the Obesity Drug Development Summit Europe in Barcelona, Spain. The study evaluated RES-010 in a non-human primate model for obesity as both a monotherapy and in combination with semaglutide, while also assessing weight control after treatment discontinuation.
RES-010 demonstrated robust and durable weight reduction effects in obese NHPs maintained on a high-fat diet. After 10 weeks of treatment, RES-010 monotherapy achieved a 15% reduction in fat mass compared to semaglutide (16%), while also preserving lean mass (-1% with RES-010 versus -8% with semaglutide). In combination with semaglutide, RES-010 provided an additive benefit resulting in a 33% reduction of fat.
After semaglutide interruption at week 10, the animals previously treated with the combination and still on RES-010 alone did not experience rebound weight gain despite a rapid increase in food intake. Four weeks after semaglutide discontinuation, animals that continued on RES-010 showed a further reduction of fat mass and a substantial recovery of lean mass. The stabilization of body weight observed with RES-010 treatment was sustained for at least 4 weeks in absence of any treatment.
RES-010 is designed to reprogram metabolic pathways, providing a potential disease-modifying therapeutic impact that could include high-quality, sustained weight loss. By specifically targeting miR-22, a master regulator of lipid biosynthesis, mitochondrial function, and adipose tissue transformation, RES-010 has the potential to go beyond conventional obesity treatments that focus solely on appetite reduction.
RES-010 is currently being evaluated in a Phase 1 trial (EUCT No.: 2024-514871-17-00) to assess the safety, tolerability, and pharmacokinetic profile of RES-010, with preliminary data expected in mid-2026.
Riccardo Panella, CSO of Resalis Therapeutics, said RES-010 delivers fat-selective weight loss, prevents rebound after GLP-1 RA discontinuation and shows durability beyond treatment.
Alessandro Toniolo, CEO of Resalis Therapeutics, said these results underscore RES-010’s potential to reshape obesity treatment.
Contact: Eva Mulder or Charlotte Spitz, +31 6 52 33 15 79, resalis@trophic.eu
Source: Resalis Therapeutics
